Gasparini Giampietro, Longo Raffaele, Sarmiento Roberta, Morabito Alessandro
Division of Medical Oncology, S Filippo Neri Hospital, Rome, Italy.
Lancet Oncol. 2003 Oct;4(10):605-15. doi: 10.1016/s1470-2045(03)01220-8.
Experimental studies have shown that cyclo-oxygenase 2 (COX2) is involved in tumour development and progression. Selective inhibitors of COX2 (coxibs) block tumour growth through many mechanisms, especially by antiangiogenic and proapoptotic effects. In experimental models, coxibs potentiate the activity of cytotoxic agents, hormones, and radiotherapy. Large clinical studies have shown chemopreventive activity of coxibs in colorectal cancer. The findings of preclinical studies coupled with the overexpression of COX2 observed in advanced human tumours are the basis for new therapeutic anticancer strategies based on combinations of coxibs with other anticancer treatment modalities. Early clinical studies have documented the feasibility, good tolerability, and promising activity of coxibs combined with chemotherapy in patients with advanced colorectal and non-small-cell lung cancers. Here, we describe the recent findings on the antitumour effects of coxibs with particular focus on the opportunities that have emerged for treatment of cancer.
实验研究表明，环氧化酶2（COX2）参与肿瘤的发生和发展。COX2选择性抑制剂（coxibs）通过多种机制阻止肿瘤生长，尤其是通过抗血管生成和促凋亡作用。在实验模型中，coxibs可增强细胞毒性药物、激素和放疗的活性。大型临床研究表明，coxibs在结直肠癌中具有化学预防活性。临床前研究结果以及在晚期人类肿瘤中观察到的COX2过表达，是基于coxibs与其他抗癌治疗方式联合应用的新型抗癌治疗策略的基础。早期临床研究已证明，coxibs联合化疗在晚期结直肠癌和非小细胞肺癌患者中具有可行性、良好的耐受性和有前景的活性。在此，我们描述coxibs抗肿瘤作用的最新研究结果，特别关注出现的癌症治疗机会。
